Affimed Announces Second Quarter 2015 Financial Results and Corporate Update Conference Call July 28, 2015
Affimed ASCO Data Demonstrate Consistent Potency of NK- Cell-Engaging Combination Therapy with Checkpoint Modulators May 29, 2015
Affimed ASCO Data for the CD33/CD3-TandAb Program Demonstrate that CD33 and CD3 binding affinities correlate with potent T-cell activation and cytotoxicity May 29, 2015
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena’s and Janssen’s Criteria and Achieves Milestone Ahead of Schedule May 24, 2015
